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Abstract
Background: There are currently no reliable markers of acute domoic acid toxicosis (DAT) for California sea lions.
We investigated whether patterns of serum peptides could diagnose acute DAT. Serum peptides were analyzed by
MALDI-TOF mass spectrometry from 107 sea lions (acute DAT n = 34; non-DAT n = 73). Artificial neural networks
(ANN) were trained using MALDI-TOF data. Individual peaks and neural networks were qualified using an
independent test set (n = 20).
Results: No single peak was a good classifier of acute DAT, and ANN models were the best predictors of acute
DAT. Performance measures for a single median ANN were: sensitivity, 100%; specificity, 60%; positive predictive
value, 71%; negative predictive value, 100%. When 101 ANNs were combined and allowed to vote for the
outcome, the performance measures were: sensitivity, 30%; specificity, 100%; positive predictive value, 100%;
negative predictive value, 59%.
Conclusions: These results suggest that MALDI-TOF peptide profiling and neural networks can perform either as a
highly sensitive (100% negative predictive value) or a highly specific (100% positive predictive value) diagnostic
tool for acute DAT. This also suggests that machine learning directed by populations of predictive models offer the
ability to modulate the predictive effort into a specific type of error.
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Background
The toxicosis associated with domoic acid (DA) inges-
tion has been linked to massive marine mammal strand-
ing events along the coastal areas of the Western United
States [1]. The California sea lion (Zalophus california-
nus) appears to be the most commonly affected species,
likely due to its foraging on fish containing domoic acid
[2]. Of sea lions admitted to The Marine Mammal Cen-
ter (TMMC; Sausalito, CA) between 1998 and 2006
more than 24% were diagnosed with domoic acid toxi-
cosis (DAT), of which 77% were acute DAT [3]. Mortal-
ity was significant, regardless of acute or chronic
diagnosis, exceeding 40%.
Arriving at a diagnosis of DAT is not always straight
forward. Clinical signs can be highly variable [4] and
diagnosis often requires post mortem information
derived from histological examination of the brain.
Some of the variability in clinical signs in stranded ani-
mals is likely due to variation in ingested dose, the time
a tw h i c ht h es e al i o ns t r a n d s ,a n dt h et i m ea tw h i c h
examination occurs during the course of the intoxica-
tion. Clinical suspicion of DAT is based on the observa-
tion of abnormal behavior, e.g., ataxia, constant head
weaving or seizures [4], which may or may not present
at the time of stranding. The diagnosis solely based
upon the detection of DA in body fluids or tissues can
be misleading because (i) DA is rapidly cleared from the
body in experimental animal models [5] and sea lions
[6], (ii) the time between ingestion and stranding is
unknown, (iii) there is no established harmful dose for
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provide information to allow a definitive diagnosis of
DAT. High hematocrit, eosinophil counts and serum
creatine kinase activities have been reported for sea
lions with DAT [4]; however, only creatine kinase activ-
ity was found to be abnormal compared with established
normal parameters for marine mammals. In a larger
study of 715 sea lion cases from 1998 to 2006, abnormal
hematological parameters were not found [3] raising the
question of utility of these parameters in the differential
diagnosis.
Diagnosis of DAT is supported by the finding, after
necropsy, of hippocampal atrophy and neuronal necrosis
[3,7], although, these changes are not always observed in
acutely affected animals. Neuropathologic changes in
hippocampal volume measured by magnetic resonance
imaging (MRI) or abnormal oscillations in brain electri-
cal activity measured by electroencephalography (EEG)
both offer less invasive means to support a diagnosis of
chronic DAT [3]. Whether or not MRI or EEG can suf-
ficiently discriminate between living sea lions with acute
DAT and stranded sea lions without DAT has not been
determined. Regardless, both MRI and EEG are expen-
sive, time consuming, and impractical as a diagnosis
tool during mass stranding events [8]. High-throughput,
less invasive clinical diagnostic tools for DAT, beyond
non-specific changes such as abnormal behavior, which
do not require sedation or post-mortem analysis are
unavailable. Recently, a semi-quantitative test for habi-
tuation to external stimuli was reported to classify sea
lions afflicted with DAT with 50% sensitivity and 93%
specificity which equates to 81% negative predictive
value, and 75% positive predictive value [8]. Although
not perfect, a behavioral test such as this does not nega-
tively impact the health of the sea lion and provides
support for the diagnosis of DAT.
Time-of-flight mass spectrometry has been used as a
clinical discovery tool for a number of human diseases
with primary emphasis in cancer [9], but also to classify
immunological diseases [10,11], response to erythropoie-
tin therapy [12], renal disease [13], and neurological dis-
orders [14,15] to name a few. The low molecular weight
proteome or peptidome found in biological fluids is
diverse and changes in the profile can be employed to
discriminate between patients with or without disease
[16]. In addition, combinations of candidate proteins/
peptides can often create a more robust test when indi-
vidual proteins/peptides fail to discriminate between two
groups [17-19]. Large transcriptomic datasets analyzed
with machine learning tools were recently shown to
enhance the ability to discriminate health status of Cali-
fornia sea lions [20]. Because clinical signs and hemato-
logical parameters offer little value towards the
diagnosis of DAT in sea lions, we investigated whether
patterns of serum peptides could offer additional sup-
port to the diagnosis of DAT using a similar machine
learning approach.
Results
Comparison of haematological and clinical parameters
Sera from stranded sea lions collected at TMMC were
distributed across multiple years between 2005 and 2010
in proportions equal to 11.5% (n = 10), 6.9% (n = 6),
16.1% (n = 14), 17.2% (n = 15), 35.6% (n = 31) and
12.6% (n = 11), from 2005 to 2010 respectively. Sera
from the MMP were collected between 2000 and 2008,
and at the time of sampling 7 of 20 exhibited clinical
signs which included regurgitation, diarrhea, lameness,
vesicles, and abscess from bite wound. Only one animal
had prior seizures but clinical signs were unrelated to
symptoms associated with DAT. Of the MMP sea lions,
15 of 20 were fasted at the time of collection and 8 of
20 blood samples were taken under anesthesia. Descrip-
tive data available for all individuals in the training data-
set is summarized in Additional file 1: Table S1.
Individuals in the stranded non-DAT group reflect etiol-
ogies common to sea lions admitted to TMMC between
1991 and 2000 [21]; of these 3,379 non-DAT individuals
the most prevalent etiologies were malnutrition (35%),
leptospirosis (30%), trauma (19%), and miscellaneous
(11%) with carcinoma present in 3% of cases [21]. In
addition to the 107 animals in the training set, we used
an independent test set of 20 animals for qualification,
and the identities and diagnoses were blinded to the pri-
mary investigator until after analysis. These 20 animals
from 2007 to 2010 were chosen by TMMC to include
10 acute-DAT and 10 stranded non-DAT, and in gen-
eral reflect the types of cases seen in the stranding
population. Descriptive data available for individuals in
the test set is summarized in Additional file 1: Table S2.
Haematological and serum biochemistry data were
available for serum collected from 76 of the 87 indivi-
duals in the DAT and stranded non-DAT groups (Table
1) and all 20 individuals in the managed non-DAT
group (See Additional file 1: Table S3). Individuals in
the acute DAT group had significantly higher red blood
cell counts, hemoglobin levels, and hematocrits com-
pared to the stranded non-DAT group or the combined
non-DAT group (including MMP sea lions), despite sig-
nificantly lower levels of BUN and BUN/creatinine
ratios (Table 1.). White blood cell counts in the DAT
group were 1.7-fold lower compared to the stranded
non-DAT group, but this difference was not significant
when compared to the combined non-DAT group (p >
0.05). Likewise banded neutrophils and lymphocytes
were significantly different in the DAT group relative to
the stranded non-DAT group (2.9-fold lower and 1.3-
fold higher, respectively), but this difference was not
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Page 2 of 12Table 1 Haematologic and serum biochemistry data of sea lions in the training dataset
Patients with Blood
data
n=2 9
Avg ± S.E.
n=4 7
Avg ± S.E.
n=2 0
Avg ± S.E.
DAT v. Stranded non-
DAT
DAT v. Combined
non-DAT
Component DAT Stranded non-
DAT
Managed non-
DAT
DAT Fold
Change
p-
value
Combined non-
DAT
DAT Fold
Change
p-
value
WBC 11.8 ± 0.5 (n =
29)
19.6 ± 1.6 (n =
42)
6.1 ± 0.6 (n =
20)
-1.7 <
0.001*
15.3 ± 1.3 (n =
62)
-1.3 0.329*
RBC 4.9 ± 0.1 (n =
29)
4.3 ± 0.1 (n =
42)
4.4 ± 0.1 (n =
20)
1.1 <
0.001*
4.3 ± 0.1 (n =
62)
1.1 <
0.001*
HGB 17.4 ± 0.5 (n =
29)
15.0 ± 0.4 (n =
42)
15.9 ± 0.5 (n =
20)
1.2 <
0.001*
15.3 ± 0.3 (n =
62)
1.1 <
0.001*
HCT 51.0 ± 1.4 (n =
29)
43.9 ± 1.1 (n =
42)
45.9 ± 1.5 (n =
20)
1.2 <
0.001*
44.5 ± 0.9 (n =
62)
1.1 <
0.001*
MCV 97 ± 4.5 (n =
29)
103 ± 0.8 (n =
42)
104 ± 1.8 (n =
20)
-1.1 0.686* 103 ± 0.8 (n =
62)
-1.1 0.749*
MCH 35 ± 0.3 (n =
29)
35 ± 0.3 (n =
42)
36 ± 0.7 (n =
20)
1.0 0.930* 35 ± 0.3 (n =
62)
1.0 0.482
MCHC 34 ± 0.2 (n =
29)
34 ± 0.2 (n =
42)
35 ± 0.2 (n =
20)
1.0 0.582* 34 ± 0.1 (n =
62)
1.0 0.502
PLT 428 ± 28 (n =
29)
414 ± 24 (n =
42)
358 ± 24 (n =
20)
1.0 0.701 396 ± 18.0 (n =
62)
1.1 0.323
RDW 15.8 ± 0.1 (n =
20)
16.2 ± 0.2 (n =
32)
15.3 ± 0.4 (n =
20)
1.0 0.054* 15.9 ± 0.2 (n =
52)
1.0 0.865*
MPV 7.7 ± 0.2 (n =
19)
8.1 ± 0.2 (n =
32)
8.7 ± 0.2 (n =
20)
-1.1 0.072 8.4 ± 0.1 (n =
52)
-1.1 0.007
Segs 6136 ± 173 (n
= 29)
6072 ± 345 (n
= 47)
3657 ± 367 (n
= 20)
1.0 0.045* 5351 ± 297 (n =
67)
1.1 0.801*
Bands 109 ± 44 (n =
29)
311 ± 80 (n =
47)
13 ± 13 (n =
20)
-2.9 0.002* 222 ± 58 (n =
67)
-2.0 0.075*
Lymphs 1429 ± 102 (n
= 29)
1123 ± 131 (n
= 47)
1818 ± 232 (n
= 20)
1.3 0.008* 1331 ± 121 (n =
67)
1.1 0.097*
Monos 231 ± 39 (n =
29)
97 ± 18 (n =
47)
389 ± 86 (n =
20)
2.4 <
0.001*
184 ± 33 (n =
67)
1.3 0.079*
Eosin 868 ± 115 (n =
29)
247 ± 59 (n =
47)
214 ± 62 (n =
20)
3.5 <
0.001*
237 ± 45 (n =
67)
3.7 <
0.001*
Na 148 ± 0.9 (n =
28)
156 ± 1.6 (n =
46)
149 ± 0.5 (n =
20)
-1.1 <
0.001*
154 ± 1.2 (n =
66)
-1.0 <
0.001*
K 4.7 ± 0.09 (n =
28)
4.3 ± 0.10 (n =
47)
4.3 ± 0.10 (n =
20)
1.1 0.026 4.3 ± 0.08 (n =
67)
1.1 0.012
Cl 109 ± 0.7 (n =
28)
119 ± 1.6 (n =
47)
108 ± 0.8 (n =
20)
-1.1 <
0.001*
115 ± 1.3 (n =
67)
-1.1 0.002*
BUN 21 ± 2.9 (n =
28)
100 ± 15.7 (n =
47)
26 ± 1.3 (n =
20)
-4.8 <
0.001*
78 ± 11.7 (n =
67)
-3.7 <
0.001*
Creatinine 0.7 ± 0.04 (n =
28)
3.1 ± 0.73 (n =
47)
1.1 ± 0.08 (n =
20)
-4.4 0.260* 2.5 ± 0.52 (n =
67)
-3.6 0.016*
Glucose 108 ± 4.9 (n =
28)
104 ± 4.0 (n =
47)
125 ± 5.2 (n =
20)
1.0 0.948* 110 ± 3.4 (n =
67)
1.0 0.394*
Ca 8.3 ± 0.12 (n =
27)
8.0 ± 0.13 (n =
47)
9.6 ± 0.12 (n =
20)
1.0 0.091* 8.5 ± 0.14 (n =
67)
1.0 0.405
P 5.1 ± 0.3 (n =
28)
8.0 ± 0.5 (n =
47)
5.7 ± 0.3 (n =
20)
-1.6 <
0.001*
7.3 ± 0.4 (n =
67)
-1.4 <
0.001*
Total Protein 7.8 ± 0.15 (n =
28)
7.8 ± 0.18 (n =
47)
7.3 ± 0.23 (n =
20)
1.0 0.771* 7.6 ± 0.14 (n =
67)
1.0 0.213*
Albumin 3.0 ± 0.11 (n =
28)
2.4 ± 0.08 (n =
47)
3.4 ± 0.05 (n =
19)
1.3 <
0.001
2.7 ± 0.08 (n =
66)
1.1 0.370
Bilirubin Total 0.5 ± 0.07 (n =
28)
0.7 ± 0.18 (n =
47)
0.2 ± 0.03 (n =
20)
-1.4 0.774* 0.5 ± 0.13 (n =
67)
1.0 0.038*
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group (p > 0.05). Monocytes were 2.4-fold higher and
eosinophils were 3.5-fold higher in sea lions with DAT
and both were significantly higher when managed sea
lions were included in the analysis. Creatine kinase was
significantly higher in the DAT group than the stranded
and combined non-DAT groups (1.3 and 1.7-fold
higher), and sorbitol dehydrogenase was significantly
lower (1.4-fold) than the stranded non-DAT group with
no data present for managed non-DAT individuals.
Levels of Na, Cl, P, Mg, and Na/K ratios were signifi-
cantly lower in the DAT group relative to the stranded
and combined non-DAT groups (1.1 to 1.0, 1.1, 1.6 to
1.4, 1.3, and 1.1-fold lower, respectively), whereas K was
significantly elevated in the DAT group (1.1-fold).
Lastly, albumin was significantly higher (1.3-fold) and
triglycerides were significantly lower (3.7 -fold) in the
DAT group than the stranded non-DAT group but
these differences were not significant when managed sea
lions were included in the analysis (p > 0.05).
MALDI-TOF profiling
Processing of MALDI-TOF generated spectra resulted in
the selection of 104 individual peaks that were used for
biomarker analysis. To determine if a single peak could
discriminate between the DAT and non-DAT group,
receiver operator characteristic (ROC) curves were gen-
erated using normalized peak height. No single peak
h a da r e au n d e rt h ec u r v e( A u R O C )>0 . 8 ,t h e r e f o r e
none were deemed excellent classifiers of DAT (Figure
1). Peaks normalized using Glu-Fib had a mean AuROC
of 0.543, ranging from 0.383 to 0.692. TIC normalized
peaks had a mean AuROC of 0.538, ranging from 0.396
0
10
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Figure 1 Distribution of AuROC for 104 peaks normalized to
Glu-Fib or TIC. Receiver operator characteristic curves were
constructed using peaks normalized to either Glu-Fib or TIC. Area
under the ROC curve (AuROC) was calculated for 104 peaks and
binned every 0.1 ± 0.05.
Table 1 Haematologic and serum biochemistry data of sea lions in the training dataset (Continued)
GGT 116 ± 11 (n =
27)
217 ± 25 (n =
47)
67 ± 7 (n = 20) -1.9 <
0.001*
172 ± 20 (n =
67)
-1.5 0.232*
AST (SGOT) 65 ± 12 (n =
28)
62 ± 11 (n =
46)
21 ± 2 (n = 20) 1.0 0.438* 49 ± 8 (n = 66) 1.3 0.045*
ALT (SGPT) 88 ± 13 (n =
28)
74 ± 8 (n = 47) 38 ± 3 (n = 20) 1.2 0.095* 63 ± 6 (n = 67) 1.4 0.002*
Alkaline Phosphatase 59 ± 23 (n =
27)
50 ± 10 (n =
47)
98 ± 9 (n = 20) 1.2 0.796* 64 ± 8 (n = 67) -1.1 0.081*
Fe 86 ± 7 (n = 24) 94 ± 6 (n = 46) 115 ± 8 (n =
20)
-1.1 0.470 100 ± 5 (n = 66) -1.2 0.150
Cholesterol 172 ± 9 (n =
28)
178 ± 10 (n =
47)
334 ± 18 (n =
20)
1.0 0.827* 224 ± 13 (n =
67)
-1.3 0.058*
Triglycerides 52 ± 4 (n = 28) 191 ± 35 (n =
47)
31 ± 4 (n = 20) -3.7 0.003* 143 ± 26 (n =
67)
-2.8 0.493*
Mg 1.9 ± 0.07 (n =
23)
2.5 ± 0.17 (n =
44)
2.6 (n = 1) -1.3 0.019* 2.5 ± 0.17 (n =
45)
-1.3 0.014*
Creatine Kinase 1881 ± 417 (n
= 27)
1434 ± 571 (n
= 46)
341 ± 101 (n =
20)
1.3 0.070* 1103 ± 403 (n =
66)
1.7 0.003*
BUN/Cr Ratio 30 ± 4 (n = 28) 55 ± 6 (n = 47) 29 ± 5 (n = 20) -1.8 <
0.001*
47 ± 5 (n = 67) -1.6 0.002*
Na/K Ratio 32 ± 0.7 (n =
28)
36 ± 1.4 (n =
47)
35 ± 0.7 (n =
20)
-1.1 0.002* 36 ± 1.0 (n =
67)
-1.1 <
0.001*
SDH (Sorbitol
Dehydrogenase)
21 ± 4 (n = 20) 30 ± 4 (n = 39) - -1.4 0.016* n.a. n.a. n.a.
A T-test (or rank sum test if distribution was non-normal, indicated by ‘*’) was used to compare blood chemistry values between groups
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Page 4 of 12to 0.754. The best individual classifier was peak 3017 m/
z (TIC normalized) which had an AuROC ± S.E. of
0.754 ± 0.054 (Figure 2). When the independent test set
was used to qualify the performance of peak 3017 m/z
with a threshold determined by minimal-misclassifica-
tion the test achieved 100% specificity but only 20% sen-
sitivity with 8 of 10 acute-DAT individuals being called
incorrectly (Table 2; Additional file 2: Table S4).
In addition to evaluating individual peak performance
for predicting DAT, we were also interested in whether
there were peaks that predicted individuals in the mana-
ged non-DAT group comprised of sea lions under long-
term care of the MMP. When performance was evalu-
ated for discriminating managed non-DAT versus
stranded individuals, 21 TIC normalized peaks had an
AuROC > 0.8 and the best performer, 1362 m/z, had an
AuROC ± S.E. of 0.979 ± 0.023 (see Additional file 3:
Figure S1). Interestingly this peak was mostly absent in
stranded sea lion sera. Using the OpT threshold, the
individuals in the managed non-DAT group were called
correctly 18 of 20 times (90% sensitivity), and of the two
mis-called sea lions (#2 and #9), sea lion #2 showed
clinical signs (behavioral; poor performance). Moreover
only four stranded individuals (CSL 6896, 9111, 9271
and 9770) were called incorrectly (95% specificity).
Using this same threshold only one individual in the
independent test set was called managed non-DAT
(CSL 9766, an adult female with acute DAT which had
recovered and was ultimately released).
Because no single peak was an excellent classifier of
DAT, unsupervised hierarchal clustering was used to
determine whether multiple peaks could separate
DAT from non-DAT sea lions (See Additional file 4:
Figure S2). The two groups did not form separate
clusters, suggesting unsupervised methods are not
capable of discriminating the complex relationship
between DAT and non-DAT. Therefore peak data
w e r em o d e l e du s i n gas u p e r v i s e di n f o r m a t i cm e t h o d :
feed-forward artificial neural networks (ANNs). Glu-
Fib and TIC normalized peaks were used separately,
and 101 ANNs were trained. In addition to using
individual ANNs, we also combined all 101 ANNs
and allowed each to vote for the outcome (CANN-
vote), or simply averaged all 101 predictions
(CANN101). The generated models were qualified
using a blinded independent test set of 20 sera from
stranded sea lions, which were diagnosed with acute
DAT (n = 10) or non-DAT (n = 10). Using decision
thresholds determined ap r i o r i ,t h ep e r f o r m a n c eo f
each model was evaluated for each of the 20 sea lions
(Table 2). Compared to the single peak 3017 m/z
which gave 100% specificity but only 20% sensitivity,
testing different individual ANNs we achieved high
specificity (100%) or high sensitivity (100%). Specifi-
cally, we found the best performance of Glu-Fib nor-
malized data was 30% sensitivity and 100% specificity,
which was achieved using a median ANN (Glu-Fib-
ANN53). Relative to ANNs trained on Glu-Fib nor-
malized data, models trained using TIC normalized
data achieved higher sensitivity (100% versus 40%) as
well as high specificity (90%; Supporting information
Tables S5 and S6). A negative predictive value of
100% was achieved using a median ANN (TIC-ANN1)
which was the highest seen in any model (Table 2).
This model predicted all 10 DAT individuals correctly
with four false positives. The four individuals that
were predicted incorrectly could not be explained by
sex, age, primary etiology or blood chemistry (See
Additional file 2: Table S4). It was also interesting to
note that peak 3017 m/z was a large contributor to
ANNs trained on TIC normalized data (Figure 3). We
also observed that other median TIC ANNs (i.e.,
ANNs with AuROCs equal to the median) had differ-
ent performance measures despite the same AuROC
(e.g., TIC-ANN1 versus TIC-ANN67;T a b l e2 ) ,a n d
overall using the OpT threshold when different from
the minMC threshold resulted in higher sensitivity
with minimum loss of specificity. For example, in the
case of TIC-ANN67, the OpT improved performance
while maintaining the same specificity as the minMC
(Table 2). When allowed to vote, we achieved 100%
specificity and 30% sensitivity (Glu-Fib-CANN-vote;
Table 2), while other CANN models did not perform
as well when 100% specificity was achieved (Support-
ing Information Tables S5 and S6).
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 0
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Figure 2 Receiver operator characteristic curve for peak 3017
m/z. The TIC normalized training dataset was used to generate an
ROC curve with an AuROC ± S.E. of 0.754 ± 0.054. Four thresholds
are shown by arrows: minimum mis-classified cut-off (hollow arrow),
optimum threshold (solid arrow), negative predictive value cut-off
(striped arrow), and positive predictive value cut-off (grey arrow).
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In this study we show patterns of serum peptides can be
used to discriminate between stranded sea lions afflicted
with acute DAT and those unaffected, with excellent
positive or negative predictive value (i.e., 100%). Cur-
rently DAT is diagnosed based on a variety of clinical
signs [3,4,22] as well as the presence of domoic acid in
body fluids [1,4], but is generally only confirmed post-
mortem [7,8,22]. Moreover, individuals are further char-
acterized along a continuum of toxicosis ranging from
acute to chronic, with the former recovering over time
and the latter progressing to status epilepticus [3,4,22].
The symptomology separating acute from chronic DAT
can be inconclusive, such as inconsistent MRI-
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Figure 3 Relative contribution of each MALDI-TOF peak to each of the 101 ANNs trained using TIC normalized data. The peaks with the
10 highest average percent contribution are indicated, with superscripted rank. Peak 1362 m/z is indicated for reference.
Table 2 Qualified performance of models using an independent test set
3017 m/z ANN1 ANN67 ANN67 ANN53 CANN-Vote
Normalization TIC TIC TIC TIC Glu-Fib Glu-Fib
AuROC 0.7538 0.9412 0.9412 0.9412 0.9428 na
Threshold
a minMC OpT OpT minMC OpT > 50 votes
Test Set sensitivity 0.20 1.00 0.40 0.70 0.30 0.30
specificity 1.00 0.60 0.90 0.90 1.00 1.00
PPV 1.00 0.71 0.80 0.88 1.00 1.00
NPV 0.56 1.00 0.60 0.75 0.59 0.59
Training Set sensitivity 0.35 0.91 0.88 0.91 0.94 1.00
specificity 0.93 0.95 1.00 0.99 0.96 0.99
PPV 0.71 0.89 1.00 0.97 0.91 0.97
NPV 0.76 0.96 0.95 0.96 0.97 1.00
a Thresholds calculated a priori based on training set data. minMC, minimum mis-classified threshold; OpT, optimum threshold (OpT).
Performance against training set is given for comparison
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Page 6 of 12observable hippocampal atrophy associated with chronic
DAT [3,7,22,23]. As a diagnostic tool MRI is expensive,
requires sedation and is impractical during a mass
stranding event [8]. Overall, the lack of a clear gold-
standard for diagnosing DAT highlights the complexity
of the underlying physiopathology. Additionally, indivi-
duals on the far end of the spectrum, chronic DAT, are
poor rehabilitation candidates and often euthanized [22].
Therefore the best test would be one that is rapid, accu-
rate (minimizing false positives), and high-throughput to
allow for immediate testing even in the absence of
abnormal behavior.
Peptide profiling by MALDI-TOF is a high-throughput
tool which is sensitive across a large dynamic range [24]
and has been used to classify diseases in humans [25]. A
major concern with any biomarker study is experimental
design [18], therefore we focused on three areas of likely
variability: DAT diagnosis, sample handling, and case-
controls. For our training set we used sera from indivi-
duals that were diagnosed with acute DAT (according
to [3,22]) without confounding etiologies and rejected
non-DAT individuals with signs of DAT (acute or
chronic). We also chose to not use pregnant females
since we assumed their blood peptide levels would be
greatly influenced by pregnancy. Pregnant females are a
key group to be addressed in future research since stu-
dies suggest pregnant females are spatially more likely
to be exposed to domoic acid [26] and approximately
25% of females admitted between 1998 and 2006 had
evidence of reproductive failure [3]. To account for
technical variability due to serum handling, specifically
the effect of serum clotting time on peptide profiles
[19,27], only sera banked at -80°C on the day of collec-
tion were utilized. In addition, sea lions were frequency
matched to control for differences in age and sex. Hae-
matologic comparisons of stranded sea lions with acute
DAT and those without showed that individuals with
acute DAT have significantly increased hematocrit, eosi-
nophil counts, and levels of creatine kinase in congru-
ence with previous reports [4,28]. Higher hematocrit
may indicate dehydration although individuals with
acute DAT had significantly lower BUN and BUN/crea-
tinine ratios that aligned with managed non-DAT indivi-
duals suggesting other influences aside from dehydration
could affect hematocrit. The clinical use of BUN and
BUN/creatinine ratio in the context of domoic acid toxi-
cosis has not been well described, but monosodium glu-
tamate administration in rats has been shown to
decrease serum BUN and creatinine while elevating
BUN/creatinine ratio [29]. We also found that acute
DAT individuals had a 1.7 to 1.3-fold reduction in white
blood cell counts compared to non-DAT individuals,
though these values are still within reported normal
ranges (9.4 to 22.8; [30]). This is contrary to reports of
dolphins exposed to DA in which there was a concur-
rent eosinophil and white blood cell increase [31].
Although haematology and serum biochemistry are use-
ful for narrowing the diagnosis, alone they cannot con-
firm specific etiologies. We postulate that these broad
differences may indicate an underlying pathology speci-
f i ct od o m o i ca c i de x p o s u r e( e.g., neuronal necrosis and
eosinophilia).
Using MALDI-TOF we selected 104 peaks in the
training set of 107 individuals to be used for calculating
different thresholds ap r i o r ifor single markers and
models based on different performance goals, e.g., high
specificity while minimizing false positives. Performance
was qualified using an independent test set since it is
known that cross-validation alone overestimates model
performance [18]. Since these peaks reflect a fraction of
the peptidome and any changes reflect changes in the
body due to the nature of blood circulation, we
hypothesized that there would be a peptide or group of
peptides that could discriminate sea lions with DAT,
but no single peak was a good discriminator of DAT
(AuROC > 0.8). Interestingly, individuals in the mana-
ged non-DAT group could be largely classified based on
the absence of peak 1362 m/z with only two managed
individuals being misclassified. Furthermore, peak 1362
m/z was able to largely discriminate the stranded popu-
lation from the managed population, with only five
stranded individuals being classified incorrectly. Because
the managed population is comprised solely of male sea
lions it is possible that 1362 m/z is a sex specific mar-
ker; however four out of five misclassified sea lions from
the stranding population were female thereby refuting
this idea. While we contend that this peak may be a
marker of stress it is also possible that differences in
sample handling may also influence the presence of this
peak [19,27]. Given the differences in peak 1362 m/z
between the managed and stranded populations we feel
additional studies are warranted to determine the iden-
tity and utility of this peptide.
Because no single peak was an excellent classifier of
DAT or non-DAT, neural network models were con-
structed to interrogate multidimensional relationships.
Previous reports have demonstrated that more than one
classifier can increase test performance, because a panel
of biomarkers is more robust to inherent biological per-
turbation and individual variation is mitigated by the
g r o u p[ 1 9 , 2 0 , 3 2 ] .S i m i l a r l y ,w ef o u n dt h a ta r t i f i c i a l
neural networks trained using all 104 peaks outper-
formed single classifiers based on increased sensitivity.
T h em o d e lt h a tg a v et h eh i g h e s ts e n s i t i v i t y( 1 0 0 % )a n d
specificity (60%), TIC-ANN1, only mis-classified four
individuals in the test set as DAT. This could not be
explained by sex, age, primary etiology or blood chemis-
try, indicating the model is not overtly biased.
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was also the best single classifier of DAT (3016 m/z)
highlighting the potential importance of this peak as a
classifier. Lastly, our results highlight the importance of
evaluating different decision thresholds, which can
improve performance and sensitivity while maintaining
specificity. This may prove invaluable in diagnosing
DAT since minimizing false positives and maintaining
acceptable sensitivity will facilitate diagnosis and
treatment.
Conclusions
Despite the need for a highly specific test for DAT, cur-
rently there is little information on the accuracy of cur-
rent DAT diagnostic approaches. We achieved 100%
sensitivity and 60% specificity in a single model (TIC-
ANN1) and demonstrated that MALDI-TOF peptide
profiling and neural networks together can perform as a
highly sensitive (with 100% NPV) or highly specific
(with 100% PPV) diagnostic tool for acute DAT.
Although the test set NPV is 100% for TIC-ANN1,t h e
training set NPV at the same threshold suggests that the
true NPV for this test is likely 96% (Table 2). This tech-
nique also has the potential to be used as a high-
throughput diagnostic tool to allow for immediate test-
ing even in the absence of abnormal behavior, although
due to the technical nature of the process it is less likely
to be a point-of-care test and better suited for a centra-
lized laboratory. Future studies will also address the use-
fulness of combined peptidomic or proteomic analysis to
discriminate sea lions with chronic DAT from sea lions
with acute DAT, which has increased in prevalence in
recent years [3]. Since samples can be drawn at the time
of admission, a prognostic test may be developed to
place individuals in risk categories and/or diagnosis on
the continuum of acute to chronic DAT based on nega-
tive outcome of individuals over time. Techniques such
as these may also provide insight into the biology of
progression from acute to chronic DAT, or markers of
DA exposure in individuals without identifiable clinical
signs. In conclusion, this test highlights the benefits and
potential of using MALDI-TOF peptide profiling as an
accurate, rapid, non-invasive, robust tool to identify sea
lions with acute DAT.
Methods
Serum collection and storage
Samples were collected by The Marine Mammal Center
(TMMC; Sausalito, CA) under IACUC approved proto-
cols and under the National Fisheries Service permit
number 932-1489-00 and by the U.S. Navy Marine
Mammal Program (MMP; San Diego, CA) as part of a
standard clinical care regime. At both locations, blood
samples were collected in serum separator tubes (SST)
and allowed to clot for 30 to 60 min, centrifuged, serum
transferred into cryovials, and stored at -80°C. Less than
7 h passed between clotting and storage at -80°C. Since
it has been shown that the number of freeze thaw cycles
can affect the measured peptide profile of frozen sera
[33], all samples were thawed at the Medical University
of South Carolina at 37°C for one min, then placed on
ice and 60 to 110 μL aliquots were stored at -80°C.
Hematology and serum biochemistry data were included
for comparison if the data corresponded to the same
day as the drawn sample.
Inclusion criteria
Individuals in this study were divided into three groups:
those suffering from acute domoic acid toxicosis (acute
DAT), individuals admitted to TMMC that were asymp-
tomatic for DAT (stranded non-DAT), and individuals
from the MMP that were asymptomatic for DAT (man-
aged non-DAT). Except for one sea lion that had just
been admitted into the MMP from TMMC, all MMP
individuals had been under the long-term care of veteri-
narians, hence were collectively deemed ‘managed’.T h e
remaining two groups, acute DAT and stranded non-
DAT were sampled at TMMC and were defined using
available clinical parameters. We retrospectively identi-
fied serum samples from California sea lions that
stranded alive along the central California coast between
2005 and 2010 (n = 2343). Of these, sera drawn within
seven days of admission to TMMC were allowed
(~2000). We included sera from both sexes and adult,
subadult, juvenile, and yearling age classes (as deter-
mined by [21]). Individuals were included in the acute
DAT group based on clinical signs such as seizures or
neurological clinical signs [4] and in some cases the pre-
sence of domoic acid in bodily fluids. Specifically, acute
DAT cases were differentiated from individuals with
chronic DAT as described by Goldstein et al. [3] or with
available brain histology (hippocampal atrophy indicated
chronic DAT; [7]). Individuals included in the stranded
non-DAT group stranded for reasons other than DAT.
Exclusion criteria
Sera from known pregnant females (i.e., those that
aborted later in rehabilitation or with a fetus in uterus
at necropsy), individuals with significant trauma (e.g.,
missing limbs or life threatening wounds), or individuals
later diagnosed with chronic DAT were excluded from
the study. Sera were excluded if collected more than
seven days after admission, by heart-stick, post-mortem,
o ri ft h e yw e r en o ta r c h i v e da t- 8 0 ° Ct h ed a yo fc o l l e c -
tion. Individuals were excluded from the acute DAT
group if there was a confounding etiology (e.g., carci-
noma or leptospirosis). Leptospirosis was diagnosed
based on blood chemistry or at necropsy (as described
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missing hematology data but had no indications of lep-
tospirosis (e.g., post-mortem kidney changes characteris-
tic of leptospirosis [21]). Conversely, individuals were
excluded from the stranded non-DAT group if seizures/
other neurological problems were observed during their
time in rehabilitation (regardless of etiology), histology
indicated brain morphological changes consistent with
DAT, they were positive for DA in bodily fluids, or if
they later stranded with signs of DAT.
Experimental design
A training sample set was analyzed followed by an inde-
pendent test set used to qualify biomarker and model
performance. The training set (n = 107) was comprised
of nearly all acute DAT sera samples available from
TMMC meeting the criteria described above, frequency
matched non-DAT sea lions, and non-frequency
matched managed samples from the MMP (See Addi-
tional file 1: Table S1). The independent test set (n =
20) was blinded to Medical University of South Carolina
personnel processing the samples and analyzing the
data. Sea lion samples included in the test set were ran-
domly chosen from the TMMC acute DAT and non-
DAT sample population prior to analysis of the training
set. Test set samples were processed and analyzed on a
day that was different than training set samples.
Furthermore, the test set was shipped separately from
the training set to avoid any handling bias between
training and test set samples. Sera from the training set
were extracted and analyzed on two different days. To
limit the effect of interday MALDI-TOF variability [27],
the training set was divided into two groups (Day 1 or
Day 2) that had equal sample proportions representing
acute DAT, stranded non-DAT, and managed sea lions.
Each group was equally represented for sex, age class,
draw year, and outcome (release or euthanasia/death).
MALDI-TOF
Immediately before being processed, serum aliquots
were thawed at 37°C for one min after which 50 μL was
transferred to a 200 μL PCR tube. Additional freeze-
thaws were not allowed. Next, each serum was diluted
to 0.1% (v/v) TFA using 100 μLo f0 . 1 5 %( v / v )T F A
(Thermo Scientific, Rockford, IL) and incubated at room
temperature for 5 min prior to the addition of 10 μL
C8-magnetic beads (ClinProt™ Profiling Kit, Bruker
Daltonics, Billerica, MA). Magnetic beads and serum
were incubated for 1 min at room temperature, followed
by three wash steps of 100 μL 0.1% (v/v) TFA according
to manufacturer’s guidelines. Peptides were eluted with
20 μL of 50% acetonitrile in stabilization buffer (Bruker
Daltonics) and 15 μL was transferred to a clean tube.
Finally, 30 μLo fm a t r i x[ 5m gm L
-1 a-cyano-4-
hydroxycinnamic acid (Bruker Daltonics) in HPLC grade
methanol:acetonitrile:water (5:4:1) containing 25 nM
glu-1-fibrinopeptide peptide mass standard (Glu-Fib;
Protea Biosciences, Inc., Morgantown, WV)] was added.
Two μL of sample matrix was spotted onto a ground
steel target plate (MTP 384 ground steel T F plate, Bru-
ker Daltonics). Matrix assisted laser desorption ioniza-
tion time of flight (MALDI-TOF) spectra were acquired
using a Bruker AutoflexIII. Each spectra is the sum of
5,000 shots with the laser moving every 1,000 shots
across a polygon pattern. A calibration mixture from the
manufacturer (Bruker Daltonics) was used to calibrate
the instrument during acquisition (every three to eight
samples) to correct for spatial and temporal drift. Reso-
lution was determined using the Glu-Fib internal stan-
dard and was 3200 with an average mass error of 148
ppm.
Data processing and analysis
Statistics on haematologic and serum biochemistry
values were performed using SigmaPlot (v. 11.2) to com-
pare two groups. A T-test was used to determine differ-
ences between two groups, with normality first being
evaluated using a Shapiro-Wilk test (a =0 . 0 5 ) .N o n -
normal data was evaluated using a Mann-Whitney Rank
Sum test (a = 0.05). Raw MALDI-TOF spectra were
processed using Progenesis MALDI (Nonlinear USA
Inc., Durham, NC). Spectra were pre-processed using a
noise filter size of 5 and background subtracted using a
top hat filter size of 200. Spectra were aligned using a
search area of 5 and 20 iterative cycles. Peaks with a
weighted average above 1500 cps were automatically
selected and manually inspected for inclusion. Peak
intensities were normalized to the internal standard
(Glu-Fib) or Total Ion Current (TIC) and analyzed sepa-
rately based on normalization procedure. If TIC was
used, Glu-Fib peaks were removed before importing
into Progenesis MALDI. The independent test set was
aligned with the training set to ensure proper peak
alignment. These data were used for downstream ana-
lyses. Additionally, Matlab (MathWorks R2010b, Natick,
MA) was used to perform unsupervised hierarchical
clustering analysis of the TIC normalized peak data
from the training set.
Receiver operator characteristic (ROC) curve analysis
Receiver operator characteristic curves were generated
and the area under the curve (AuROC) was determined
using Matlab. A 95% confidence interval for each
AuROC was determined by calculating the standard
error according to Hanley et al. [34] with a = 0.05. Four
different thresholds were calculated: minimum mis-clas-
sified threshold (minMC), optimum threshold (OpT),
100% negative predictive value (NPV; proportion of
Neely et al. Proteome Science 2012, 10:18
http://www.proteomesci.com/content/10/1/18
Page 9 of 12predicted negatives which are true negatives) threshold
(npvT) and 100% positive predictive value (PPV; propor-
tion of predicted positives which are true positives)
threshold (ppvT). The minMC is the threshold that
minimizes the proportion of false-negatives and false-
positives. The OpT is the geometrically determined
threshold which is the closest point to 100% sensitivity
and 100% specificity which corresponds to the perfect
test [35]. The npvT and ppvT are the thresholds with
the highest specificity and 100% NPV or the highest
sensitivity and 100% PPV, respectively.
Artificial neural network analysis
The artificial neural network (ANN) algorithm was
trained using Glu-Fib peptide or TIC normalized peak
data from the training dataset. These training sets were
used independently to train 101 feed-forward ANNs
performed by Matlab as previously described [36].
Briefly, each ANN was pursued to an early stop criteria
determined by internal testing using bootstrapped cross-
validation with every seventh sample, in addition to
screening for optimal topology. The median performing
ANN, determined using AuROC values, were selected
for qualification with the independent test set. In the
case where the median ANN shared identical AuROC
values, both were selected for qualification. It is impor-
tant to note that, to avoid model over-fitting, ap r i o r i
threshold values determined by ROC analysis of the
training set were utilized as decision threshold values
for qualification of the test set.
In a separate analysis, we determined statistical perfor-
mance measures for each of the 101 ANNs using the
test dataset for all thresholds (minMC, OpT, npvT,
ppvT) and both normalization procedures (TIC and
Glu-Fib), which resulted in a total of 808 tests. The
ANN output was averaged across the 101 ANNs for
each sea lion and was referred to as Combinatorial
ANN (CANN101). A priori threshold values for qualifica-
tion of the test set by CANN101 models were derived by
ROC analysis of the averaged ANN output. In addition
to CANN101 we developed a scheme to allow each of
the 101 ANNs to “vote”. This was accomplished by con-
verting the ANN outputs > 0.5 to 1’sa n ds u m m i n gt h e
values for each sea lion. If the sum of the 101 ANNs for
a sea lion was > 50, then that sea lion was predicted to
be DAT.
Additional material
Additional file 1: Table S1. Descriptive data of sea lions in the training
dataset. Trauma included lacerations, bite wounds, broken bones, and
anophthalmia. Pneumonia included verminous and/or parafilaroides.
Table S2. Descriptive data of sea lions in the independent test set.
Trauma was only to the flipper, and unknown was best described as
lethargic. Pneumonia included parafilaroides. Empty categories under
‘Primary Etiology’ given to serve as a reference to training set descriptive
data. Table S3. Haematologic and serum biochemistry data of sea lions
in the independent test set. Blood chemistry data is based on analysis of
blood drawn the same day as serum samples used for analysis. A T-test
(or rank sum test if distribution was non-normal, indicated by ‘*’) was
used to compare blood chemistry values.
Additional file 2: Table S4. Qualified performance of peak 3017 m/z
using an independent test set. DAT is indicated by a ‘1’ and non-DAT a
‘0’. Performance against training set is given for comparison. Table S5.
Qualified performance of ANNs trained with Glu-Fib normalized data.
Performance was qualified using an independent test set. DAT is
indicated by a ‘1’ and non-DAT a ‘0’. Performance against training set is
given for comparison. Table S6. Qualified performance of ANNs trained
with TIC normalized data. Performance was qualified using an
independent test set. DAT is indicated by a ‘1’ and non-DAT a ‘0’.
Performance against training set is given for comparison.
Additional file 3: Figure S1. Peak 1362 m/z spectra, ROC curve and
performance. (A) 1362 m/z peak height was plotted between two
groups. The dotted line corresponds to the threshold determined by
ROC curve analysis. (B) An ROC curve was generated using 107
individuals in the training set and was used to determine the optimum
threshold (OpT; indicated by arrow). (C) The OpT was used to determine
statistical performance measures of peak 1362 m/z using the 107
individuals in the training set. (D) Statistical performance measures for
peak 1362 m/z when all sea lions in the study (Training + Test) were
combined.
Additional file 4: Figure S2. Unsupervised clustering of MALDI-TOF
profiles of the training set. Data were standardized by each peak (n =
104; rows) and represented such that the mean is 0 and standard
deviation is ± around this mean. Columns are individuals (n = 107),
labeled at the top with red squares for acute-DAT and blue squares for
non-DAT.
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